| Market Cap | $7.84M-39.9% |
| Revenue (ttm) | n/a |
| Net Income | -$14.67M |
| EPS | -$1.19 |
| Shares Out | 11.95M |
| PE Ratio | n/a |
| Forward PE | -0.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 145,405 |
| Open | $0.73 |
| Previous Close | $0.71 |
| Day's Range | $0.64 - $0.73 |
| 52-Week Range | $0.64 - $1.88 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | $14.00(+2034.15%) |
| Earnings Date | n/a |
About PHIO
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Phio Pharmaceuticals Corp. Stock Analysis — InsiderScore
Phio Pharmaceuticals Corp. scored higher than 81% of companies evaluated by InsiderBuying, and ranked 15th out of 96 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Phio Pharmaceuticals Corp. bought $104.8K of stock across 11 purchases in the last 90 days, the largest of them $20.5K.
The average purchase added about 17% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating PHIO in the last 3 months, one vote each. Issuer-paid research is not counted.
$PHIO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PHIO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PHIO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PHIO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PHIO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PHIO from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from PHIO’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+20.6 since Sep 8Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
